EDX Medical has revealed its new suite of products and services designed to evaluate hereditary cancer risk. The tests are developed based on comprehensive hereditary gremlin cancer testing designed to test the risk of cancer of family members of diagnosed cancer patients.
Its pan-cancer test is claimed to have 99% sensitivity and the ability to identify mutations in 70 genes known to be associated with cancers such as prostate, breast, colorectal, pancreatic, and ovarian cancer. The tests will be made available through specific NHS Genetic and Genomic Testing Centres and certain private healthcare providers in late 2024. The company will also be providing support services for healthcare professionals who will be using the tests.
UK-based EDX Medical Group is a digital diagnostics company focused on developing and delivering testing solutions. Its primary offerings include digital diagnostic products and services targeting cancer, cardiovascular disease, neurology, and infectious diseases. The company's approach combines advanced biological and digital technologies to improve disease risk detection and personalize disease management efficiently.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.